Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 7;47(4):253.
doi: 10.3390/cimb47040253.

As2S2 Mediates the ROS/P38 MAPK Signaling Pathway to Induce Apoptosis and S-Phase Arrest in Myelodysplastic Syndrome Cells

Affiliations

As2S2 Mediates the ROS/P38 MAPK Signaling Pathway to Induce Apoptosis and S-Phase Arrest in Myelodysplastic Syndrome Cells

Pengjie Chen et al. Curr Issues Mol Biol. .

Abstract

Myelodysplastic syndrome (MDS) is a heterogeneous myeloid clonal disorder that represents a significant threat to human health. As2S2, a natural compound, has been shown to exert therapeutic effects on various malignant tumors, including acute myeloid leukemia (AML), breast cancer, and osteosarcoma, based on extensive clinical experience. In this study, we investigated the mechanism by which As2S2 inhibits the proliferation of the myelodysplastic syndrome (MDS) SKM-1 cell line. Our findings revealed that As2S2 inhibited the proliferation of SKM-1 cells in a time- and dose-dependent manner. Flow cytometry, protein immunoblotting, and real-time fluorescence quantitative PCR analyses demonstrated that As2S2 promotes the phosphorylation of P38 MAPK, thereby activating the MAPK signaling pathway. Additionally, it promotes apoptosis by increasing the BAX/Bcl-2 ratio and induces S-phase arrest through the downregulation of the cell cycle-related protein cyclin A2. Further studies demonstrated that As2S2-treated cells exhibited ROS accumulation under fluorescence microscopy, along with activation of the P38 MAPK signaling pathway, increased apoptosis, and S-phase arrest in the cell cycle. This process could be partially reversed by the ROS inhibitor N-acetylcysteine. Therefore, the results of the present study suggest that As2S2 induces ROS accumulation in SKM-1 cells, which contributes to the activation of the P38 MAPK signaling pathway, promoting apoptosis and S-phase arrest in the cell cycle. Additionally, As2S2 may serve as a potent therapeutic agent for the treatment of myelodysplastic syndromes, with ROS acting as one of the key therapeutic targets.

Keywords: As2S2; P38 MAPK; ROS; apoptosis; myelodysplastic syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Inhibitory effect of As2S2 on SKM-1 cells. The inhibitory effect of As2S2 on SKM-1 cells was time- and dose-dependent, with IC50 values of 22.33, 15.16, and 3.973 μM/L at 12, 24, and 48 h, respectively (X¯ ± s; n = 3).
Figure 2
Figure 2
Effects of co-culture of As2S2 and inhibitors SB203580 (10 μM/L) and NAC (300 mM/L) on apoptosis and cell cycle of SKM-1 cells. (A) Effect of co-culture of As2S2 and the inhibitor SB203580 on apoptosis levels in SKM-1 cells. (B) Flow cytometric fluorescence scatter plots of SKM-1 cell apoptosis ((B(1)): control group; (B(2)): As2S2 group; (B(3)): As2S2 and SB203580 co-culture group; (B(4)): As2S2 and NAC co-culture group). (C) Effect of co-culture of As2S2 and inhibitors SB203580 and NAC on the cell cycle. (D) Histograms of flow cytometry cell cycle distribution ((D(1)): control group, (D(2)): As2S2 group, (D(3)): co-culture of As2S2 and inhibitor SB203580, (D(4)): co-culture of As2S2 and inhibitor NAC). X¯ ± s; n = 3; ** p < 0.01 vs. control group; p < 0.01 vs. As2S2 group; ▲▲ p < 0.01 vs. As2S2 group.
Figure 3
Figure 3
Effect of co-culture of As2S2 and inhibitors SB203580 (10 μM/L) and NAC (300 mM/L) on apoptosis and cell cycle-regulated proteins in SKM-1 cells. (A) Effect of co-culture of the As2S2 group and inhibitor on the transcript levels of P38 MAPK, BAX, BCL-2, and cyclin A2 mRNA in SKM-1 cells. (B,C) Effect of co-culture of As2S2 and inhibitor SB203580 on protein expression levels and quantitative analysis in SKM-1 cells. (X¯ ± s; n = 3) ** p < 0.01 vs. control group; ▲▲ p < 0.01 vs. As2S2 group.
Figure 4
Figure 4
Effect of co-culture of As2S2 and ROS inhibitor NAC on SKM-1 cells. (A) Levels of ROS in SKM-1 cells as measured by flow cytometry. (B) Flow fluorescence histogram of ROS. (C) The expression level of ROS in SKM-1 cells observed under a fluorescence microscope (100×, (C(1)): control group, (C(2)): As2S2 group, (C(3)): As2S2 + NAC group). Arrows indicate cells exhibiting pronounced DCF fluorescence, signifying elevated reactive oxygen species (ROS) levels. (D) Effects of co-culture of As2S2 with SB203580 (P38 inhibitor, 10 μM/L) and NAC (ROS inhibitor, 300 mM/L) on cell viability of SKM-1 cells for 48 h. (E,F) Effect of co-culture of As2S2 and ROS inhibitor NAC on protein expression levels and quantitative analysis. (X¯ ± s; n = 3) ** p < 0.01 vs. control group; p < 0.01 vs. As2S2 group; ▲▲ p < 0.01 vs. As2S2 group.
Figure 4
Figure 4
Effect of co-culture of As2S2 and ROS inhibitor NAC on SKM-1 cells. (A) Levels of ROS in SKM-1 cells as measured by flow cytometry. (B) Flow fluorescence histogram of ROS. (C) The expression level of ROS in SKM-1 cells observed under a fluorescence microscope (100×, (C(1)): control group, (C(2)): As2S2 group, (C(3)): As2S2 + NAC group). Arrows indicate cells exhibiting pronounced DCF fluorescence, signifying elevated reactive oxygen species (ROS) levels. (D) Effects of co-culture of As2S2 with SB203580 (P38 inhibitor, 10 μM/L) and NAC (ROS inhibitor, 300 mM/L) on cell viability of SKM-1 cells for 48 h. (E,F) Effect of co-culture of As2S2 and ROS inhibitor NAC on protein expression levels and quantitative analysis. (X¯ ± s; n = 3) ** p < 0.01 vs. control group; p < 0.01 vs. As2S2 group; ▲▲ p < 0.01 vs. As2S2 group.

Similar articles

References

    1. Cazzola M. Myelodysplastic Syndromes. N. Engl. J. Med. 2020;383:1358–1374. doi: 10.1056/nejmra1904794. - DOI - PubMed
    1. Arber D.A., Orazi A., Hasserjian R., Thiele J., Borowitz M.J., Le Beau M.M., Bloomfield C.D., Cazzola M., Vardiman J.W. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood J. Am. Soc. Hematol. 2016;127:2391–2405. doi: 10.1182/blood-2016-03-643544. - DOI - PubMed
    1. Buckstein R.J. Integrating patient-centered factors in the risk assessment of MDS. Blood J. Am. Soc. Hematol. 2019;2019:373–380. doi: 10.1182/hematology.2019000041. - DOI - PMC - PubMed
    1. Sekeres M.A., Taylor J. Diagnosis and Treatment of Myelodysplastic Syndromes. JAMA. 2022;328:872–880. doi: 10.1001/jama.2022.14578. - DOI - PubMed
    1. Hu X.-M., Yuan B., Tanaka S., Song M.-M., Onda K., Tohyama K., Zhou A.-X., Toyoda H., Hirano T. Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines. Hematology. 2013;19:352–360. doi: 10.1179/1607845413y.0000000138. - DOI - PubMed

LinkOut - more resources